I’m pleased to share the news that this week we launched RxOutcome.

RxOutcome is a powerful new dashboard on the AdverseEvents Explorer platform that allows our clients to compare drugs across an indication, class, or mechanism of action.

With RxOutcome, subscribers can now compare actual incidence rates and patient outcome rates of a group of medications to see which drug is the safest option or which drug causes particular safety issues versus others in its peer group.

One of the keys to making this functionality work is the patient population data that we’ve obtained and added to our platform from our partners at Evaluate Limited.  We now have these patient population data integrated throughout our site on over 700 prescription drugs.  These data, combined with our market-leading post approval drug safety data and label analysis, enable our users to look at the drug safety landscape in ways never before imagined.


Related Read: Data, Disproportionality, & Drug Safety Communications


For example, when we look at the Multiple Sclerosis market, we can now see how all of the drugs indicated for the treatment for MS compared on the basis of serious outcome rate, hospitalization rate, serious adverse event rate, and DME (FDA’s Designated Medical Event) rate:


RxOutcome - Indications - multiple sclerosis


Here, we’re showing that Tysabri is presenting with highest rates in all categories.

Digging deeper into the RxOutcome dashboard, we can then examine specific serious adverse events to see how key drugs compare.  For example, one of the more noteworthy adverse events associated with Multiple Sclerosis medications is PML (Progressive Multifocal Leukoencephalopathy). 

Using the comparison grid on RxOutcome, we can see the comparative rates of PML in all of the drugs indicated for treatment of MS (where at least 5 cases have been reported).   The label status for each drug is provided so that our clients can see whether the risk is already on the label or is likely to be added to the label based on our proprietary RxSignal analysis.


RxOutcome Indication Report

As you can see, we highlight Tysabri as having the highest rate of reported cases of PML with an incidence rate of roughly 8 per 1000 patients exposed.

So, what else can our clients do with this new dashboard?  RxOutcome is designed to seamlessly integrate with all Health Economics and Outcomes Research (HEOR) and Comparative Effectiveness Research (CER) models and frameworks.  We expect this new visibility into outcome and adverse event rates will finally enable our clients to quickly and accurately assess a drug’s true post-marketed safety profile.


Related Read: The State of Drug Safety Systems


As Chief Product Officer, I am very proud of this developmental achievement and am even more excited to launch the future value-added features that we have in the hopper over the coming weeks and months.

If you are already a client and schedule a full training session on the new RxOutcome dashboard

Or learn more about RxOutcome and the rest of the data, analytics, and insight that we provide at AdverseEvents


Related Read: The Cost of Drug Safety

Sign Up Now! RxOutcome

Robert Kyle

Robert Kyle

Chief Product Officer

Robert Kyle Linkedin

Topics: Drug Safety

Bob Kyle

Written by Bob Kyle